LAUSR: crpc patients

Computational study involving identification of endocrine disrupting potential of herbicides: Its implication in TDS and cancer progression in CRPC patients.

Sign Up to like & get
recommendations!
0 Published in 2017 at "Chemosphere"

DOI: 10.1016/j.chemosphere.2017.01.054

Abstract: Several environmental pollutants, including herbicides, act as endocrine disrupting chemicals (EDCs). They can cause cancer, diabetes, obesity, metabolic diseases and developmental problems. Present study was conducted to screen 608 herbicides for evaluating their endocrine disrupting… read more here.

Keywords: disrupting potential; endocrine disrupting; study; cancer ... See more keywords

Circulating androgen receptor and serum chromogranin A in castration-resistant prostate cancers (CRPC) patients treated with abiraterone and enzalutamide.

Sign Up to like & get
recommendations!
0 Published in 2017 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2017.35.6_suppl.160

Abstract: 160Background: Circulating aberrations (copy number/point mutation] of androgen receptor (AR) as well as serum chromogranin A (CgA) have been associated to treatment response and clinical outcome in CRPC patients (pts) treated with abiraterone (abi)/enzalutamide(enza). Methods:… read more here.

Keywords: treated abiraterone; androgen receptor; crpc patients; serum chromogranin ... See more keywords

Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression.

Sign Up to like & get
recommendations!
1 Published in 2017 at "Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia"

DOI: 10.5507/bp.2017.022

Abstract: BACKGROUND AND AIMS Metastases are a severe complication in cancer patients and biomarkers predicting their progression are still lacking for specific groups of patients. HER2 positive breast cancer (HER2 BC) patients on trastuzumab therapy are… read more here.

Keywords: tumor cells; mmp; circulating tumor; progression ... See more keywords

LAUSR

You are not signed in:

Sign Up!

Computational study involving identification of endocrine disrupting potential of herbicides: Its implication in TDS and cancer progression in CRPC patients.

Circulating androgen receptor and serum chromogranin A in castration-resistant prostate cancers (CRPC) patients treated with abiraterone and enzalutamide.

Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression.